Study Highlights Promising New Treatment Option for Patients With Treatment-Resistant Acute Myeloid Leukemia
The Clinical Leukemia Service at Roswell Park Comprehensive Cancer Center helped lead the first clinical trial of the experimental oral drug ziftomenib in patients with acute myeloid leukemia (AML).
30-Sep-2024 7:05 PM EDT
Add to Favorites